Literature DB >> 6124716

Improvement of cellular immunity and IgA production in immunodeficient children after treatment with synthetic serum thymic factor (FTS).

P Bordigoni, G Faure, M C Bene, M Dardenne, J F Bach, J Duheille, D Olive.   

Abstract

Three children with IgA and IgE deficiency and T-cell defects (two related patients with ataxia telangiectasia and one with common variable immune deficiency) were treated with synthetic serum thymic factor (FTS) intravenously. A reduction in frequency and severity of infection was noted concomitantly with improvement in cell-mediated-immunity tests. Serum IgA, which was absent in two patients, appeared within 4 weeks of treatment and increased significantly in the third patient. Specific antibodies against vaccination antigens appeared for the first time or increased to titres higher than ever before. In two patients, transient interruption of FTS administration was followed by a regression of the immunological improvement, but this disappeared after the treatment was started again.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6124716     DOI: 10.1016/s0140-6736(82)90271-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  11 in total

Review 1.  Thymulin, a zinc-dependent hormone.

Authors:  J F Bach; M Dardenne
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

Review 2.  Functional anatomy of the thymic microenvironment.

Authors:  M D Kendall
Journal:  J Anat       Date:  1991-08       Impact factor: 2.610

3.  The wasted mutant mouse. II. Immunological abnormalities in a mouse described as a model of ataxia-telangiectasia.

Authors:  D Kaiserlian; W Savino; J Uriel; J Hassid; M Dardenne; J F Bach
Journal:  Clin Exp Immunol       Date:  1986-03       Impact factor: 4.330

4.  Thymic factor-induced reduction of pulmonary metastases in mice with FSA-1 fibrosarcoma.

Authors:  V J Tomazic; C R Sacasa; A Loftus; C S Suter; G E Elias
Journal:  Clin Exp Metastasis       Date:  1988 Jan-Feb       Impact factor: 5.150

5.  Thymopentin treatment of selective IgA deficiency.

Authors:  M Fiorilli; I Quinti; G Russi; R Seminara; B Ensoli; F Aiuti
Journal:  Surv Immunol Res       Date:  1985

6.  The clinical use of monoclonal anti-T-cell antibodies.

Authors:  J F Bach; L Chatenoud
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

7.  Serum thymulin in human zinc deficiency.

Authors:  A S Prasad; S Meftah; J Abdallah; J Kaplan; G J Brewer; J F Bach; M Dardenne
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

8.  Antibody responses in vivo in chromosome instability syndromes with immunodeficiency.

Authors:  C M Weemaes; T H The; P J van Munster; J A Bakkeren
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

9.  Controlled trial of a thymic hormone extract (Thymostimulin) in 'autoimmune' chronic active hepatitis.

Authors:  J E Hegarty; K T Nouri Aria; A L Eddleston; R Williams
Journal:  Gut       Date:  1984-03       Impact factor: 23.059

10.  Placental transfer of maternally-derived IgA precludes the use of guthrie card eluates as a screening tool for primary immunodeficiency diseases.

Authors:  Stephan Borte; Magdalena Janzi; Qiang Pan-Hammarström; Ulrika von Döbeln; Lennart Nordvall; Jacek Winiarski; Anders Fasth; Lennart Hammarström
Journal:  PLoS One       Date:  2012-08-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.